Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol's Belatacept Could See Approval In Second Quarter After GMP Delay

This article was originally published in The Pink Sheet Daily

Executive Summary

The kidney transplant drug Nulojix (belatacept) is finished at the plant in Puerto Rico that won't be inspection-ready until the end of the year following a August warning letter.

You may also be interested in...



Bristol/Pfizer's Apixaban Gets A Chance At The Inside Track

FDA has agreed to review the anticoagulant based on the results of the AVERROES trial, offering a potentially faster route to market.

Latest FDA Warning Letters Highlight Aseptic Processing Issues

A number of recent FDA warning letters focused on GMP issues with aseptic processing, signaling the agency’s continuing concern about contamination prevention.

When A REMS Is Not Enough: BMS Needs More Safety Data For Belatacept

FDA's "complete response" letter for kidney transplant drug does not require that Bristol-Myers Squibb do additional clinical trials, but firm must provide updates from ongoing study before approval.

Related Content

Topics

UsernamePublicRestriction

Register

PS071364

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel